Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.
H. I. Scher
Consultant or Advisory Role - Cougar Biotechnology; Veridex
Honoraria - Cougar Biotechnology
G. Heller
Consultant or Advisory Role - Veridex (U)
A. Molina
Employment or Leadership Position - Cougar Biotechnology
Stock Ownership - Johnson & Johnson
T. S. Kheoh
Employment or Leadership Position - Cougar Biotechnology
Stock Ownership - Johnson & Johnson
G. Attard
Employment or Leadership Position - The Institute of Cancer Research
Other Remuneration - The Institute of Cancer Research
J. Moreira
No relevant relationships to disclose
S. K. Sandhu
No relevant relationships to disclose
C. Parker
Honoraria - Janssen-Ortho
C. Logothetis
Consultant or Advisory Role - Cougar Biotechnology
Honoraria - Cougar Biotechnology
Research Funding - Cougar Biotechnology
R. T. McCormack
Employment or Leadership Position - Veridex
Stock Ownership - Johnson & Johnson
K. Fizazi
Employment or Leadership Position - Cougar Biotechnology
Consultant or Advisory Role - Cougar Biotechnology; Janssen-Ortho
Honoraria - Cougar Biotechnology; Janssen-Ortho
A. Anand
No relevant relationships to disclose
D. C. Danila
Consultant or Advisory Role - Cougar Biotechnology (U)
M. Fleisher
No relevant relationships to disclose
D. Olmos
Honoraria - Veridex
C. M. Haqq
Employment or Leadership Position - Ortho Biotech
Stock Ownership - Johnson & Johnson
J. S. De Bono
Honoraria - Johnson & Johnson